Your browser doesn't support javascript.
loading
Structural characterization of ß-propiolactone inactivated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) particles.
Bagrov, Dmitry V; Glukhov, Grigory S; Moiseenko, Andrey V; Karlova, Maria G; Litvinov, Daniil S; Zaitsev, Petr А; Kozlovskaya, Liubov I; Shishova, Anna A; Kovpak, Anastasia A; Ivin, Yury Y; Piniaeva, Anastasia N; Oksanich, Alexey S; Volok, Viktor P; Osolodkin, Dmitry I; Ishmukhametov, Aydar A; Egorov, Alexey M; Shaitan, Konstantin V; Kirpichnikov, Mikhail P; Sokolova, Olga S.
Afiliação
  • Bagrov DV; Faculty of Biology, Lomonosov Moscow State University, Moscow, Russia.
  • Glukhov GS; Faculty of Chemistry, Lomonosov Moscow State University, Moscow, Russia.
  • Moiseenko AV; Faculty of Biology, Lomonosov Moscow State University, Moscow, Russia.
  • Karlova MG; Faculty of Biology, Lomonosov Moscow State University, Moscow, Russia.
  • Litvinov DS; N. N. Semenov Federal Research Center for Chemical Physics, Russian Academy of Sciences, Moscow, Russia.
  • Zaitsev PА; Faculty of Biology, Lomonosov Moscow State University, Moscow, Russia.
  • Kozlovskaya LI; Faculty of Biology, Lomonosov Moscow State University, Moscow, Russia.
  • Shishova AA; Faculty of Biology, Lomonosov Moscow State University, Moscow, Russia.
  • Kovpak AA; Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences (Institute of Poliomyelitis), Moscow, Russia.
  • Ivin YY; Institute of Translational Medicine and Biotechnology, Sechenov First Moscow State Medical University, Moscow, Russia.
  • Piniaeva AN; Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences (Institute of Poliomyelitis), Moscow, Russia.
  • Oksanich AS; Institute of Translational Medicine and Biotechnology, Sechenov First Moscow State Medical University, Moscow, Russia.
  • Volok VP; Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences (Institute of Poliomyelitis), Moscow, Russia.
  • Osolodkin DI; Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences (Institute of Poliomyelitis), Moscow, Russia.
  • Ishmukhametov AA; Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences (Institute of Poliomyelitis), Moscow, Russia.
  • Egorov AM; Mechnikov Research Institute of Vaccines and Sera, Moscow, Russia.
  • Shaitan KV; Faculty of Biology, Lomonosov Moscow State University, Moscow, Russia.
  • Kirpichnikov MP; Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences (Institute of Poliomyelitis), Moscow, Russia.
  • Sokolova OS; Faculty of Chemistry, Lomonosov Moscow State University, Moscow, Russia.
Microsc Res Tech ; 85(2): 562-569, 2022 Feb.
Article em En | MEDLINE | ID: mdl-34498784
ABSTRACT
The severe COVID-19 pandemic drives the research toward the SARS-CoV-2 virion structure and the possible therapies against it. Here, we characterized the ß-propiolactone inactivated SARS-CoV-2 virions using transmission electron microscopy (TEM) and atomic force microscopy (AFM). We compared the SARS-CoV-2 samples purified by two consecutive chromatographic procedures (size exclusion chromatography [SEC], followed by ion-exchange chromatography [IEC]) with samples purified by ultracentrifugation. The samples prepared using SEC and IEC retained more spikes on the surface than the ones prepared using ultracentrifugation, as confirmed by TEM and AFM. TEM showed that the spike (S) proteins were in the pre-fusion conformation. Notably, the S proteins could be recognized by specific monoclonal antibodies. Analytical TEM showed that the inactivated virions retained nucleic acid. Altogether, we demonstrated that the inactivated SARS-CoV-2 virions retain the structural features of native viruses and provide a prospective vaccine candidate.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Propiolactona / COVID-19 Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Propiolactona / COVID-19 Idioma: En Ano de publicação: 2022 Tipo de documento: Article